Tuley, A. & Fast, W. The taxonomy of covalent inhibitors. Biochemistry 57, 3326–3337 (2018). This review summarizes the mechanisms of covalent inhibition of enzymes and comprehensively covers examples for each mechanism.
CAS PubMed Article Google Scholar
Singh, J., Petter, R. C., Baillie, T. A. & Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10, 307–317 (2011). This review illustrates the key features of covalent drug discovery with emphasis on targeted covalent inhibitors.
CAS PubMed Article Google Scholar
Ghosh, A. K., Samanta, I., Mondal, A. & Liu, W. R. Covalent inhibition in drug discovery. ChemMedChem 14, 889–906 (2019).
CAS PubMed PubMed Central Article Google Scholar
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K. & Moitessier, N. Covalent inhibitors design and discovery. Eur. J. Med. Chem. 138, 96–114 (2017).
PubMed Article CAS Google Scholar
Sutanto, F., Konstantinidou, M. & Dömling, A. Covalent inhibitors: a rational approach to drug discovery. RSC Med. Chem. 11, 876–884 (2020).
CAS PubMed PubMed Central Article Google Scholar
Zhang, T., Hatcher, J. M., Teng, M., Gray, N. S. & Kostic, M. Recent advances in selective and irreversible covalent ligand development and validation. Cell Chem. Biol. 26, 1486–1500 (2019).
CAS PubMed PubMed Central Article Google Scholar
Lonsdale, R. & Ward, R. A. Structure-based design of targeted covalent inhibitors. Chem. Soc. Rev. 47, 3816–3830 (2018).
CAS PubMed Article Google Scholar
Sagonowsky, E. The top 20 drugs by worldwide sales in 2020. Fierce Pharma https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales (2021).
Moore, A. R., Rosenberg, S. C., McCormick, F. & Malek, S. RAS-targeted therapies: is the undruggable drugged? Nat. Rev. Drug Discov. 19, 533–552 (2020).
CAS PubMed PubMed Central Article Google Scholar
Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target. Ther. 6, 386 (2021).
PubMed PubMed Central Article CAS Google Scholar
Vandyck, K. & Deval, J. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Curr. Opin. Virol. 49, 36–40 (2021).
CAS PubMed PubMed Central Article Google Scholar
Lagoutte, R., Patouret, R. & Winssinger, N. Covalent inhibitors: an opportunity for rational target selectivity. Curr. Opin. Chem. Biol. 39, 54–63 (2017).
CAS PubMed Article Google Scholar
Lu, W. et al. Fragment-based covalent ligand discovery. RSC Chem. Biol. 2, 354–367 (2021).
CAS PubMed PubMed Central Article Google Scholar
Spradlin, J. N., Zhang, E. & Nomura, D. K. Reimagining druggability using chemoproteomic platforms. Acc. Chem. Res. 54, 1801–1813 (2021).
CAS PubMed Article Google Scholar
Roberts, A. M., Ward, C. C. & Nomura, D. K. Activity-based protein profiling for mapping and pharmacologically interrogating proteome-wide ligandable hotspots. Curr. Opin. Biotechnol. 43, 25–33 (2017).
CAS PubMed Article Google Scholar
Drewes, G. & Knapp, S. Chemoproteomics and chemical probes for target discovery. Trends Biotechnol. 36, 1275–1286 (2018).
CAS PubMed Article Google Scholar
Moellering, R. E. & Cravatt, B. F. How chemoproteomics can enable drug discovery and development. Chem. Biol. 19, 11–22 (2012).
CAS PubMed PubMed Central Article Google Scholar
Maurais, A. J. & Weerapana, E. Reactive-cysteine profiling for drug discovery. Curr. Opin. Chem. Biol. 50, 29–36 (2019).
CAS PubMed PubMed Central Article Google Scholar
Chandrasekharan, N. & Simmons, D. L. The cyclooxygenases. Genome Biol. 5, 241 (2004).
CAS PubMed PubMed Central Article Google Scholar
Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231, 232–235 (1971).
Nicola, G., Tomberg, J., Pratt, R. F., Nicholas, R. A. & Davies, C. Crystal structures of covalent complexes of β-lactam antibiotics with Escherichia coli penicillin-binding protein 5: toward an understanding of antibiotic specificity. Biochemistry 49, 8094–8104 (2010).
CAS PubMed Article Google Scholar
Dijkmans, A. C. et al. Fosfomycin: pharmacological, clinical and future perspectives. Antibiotics 6, 24 (2017).
PubMed Central Article CAS Google Scholar
Hendlin, D. et al. Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science 166, 122–123 (1969).
CAS PubMed Article Google Scholar
Kahan, F. M., Kahan, J. S., Cassidy, P. J. & Kropp, H. The mechanism of action of fosfomycin (phosphonomycin). Ann. NY Acad. Sci. 235, 364–386 (1974).
CAS PubMed Article Google Scholar
Olbe, L., Carlsson, E. & Lindberg, P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat. Rev. Drug Discov. 2, 132–139 (2003).
CAS PubMed Article Google Scholar
Savi, P. et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. 84, 891–896 (2000).
CAS PubMed Article Google Scholar
Thomas, D. & Zalcberg, J. 5-Fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin. Exp. Pharmacol. Physiol. 25, 887–895 (1998).
CAS PubMed Article Google Scholar
Danenberg, P. V., Langenbach, R. J. & Heidelberger, C. Fluorinated pyrimidines. Structures of reversible and irreversible complexes of thymidylate synthetase and fluorinated pyrimidine nucleotidest. Biochemistry 13, 926–933 (1974).
CAS PubMed Article Google Scholar
Xu, H., Faber, C., Uchiki, T., Racca, J. & Dealwis, C. Structures of eukaryotic ribonucleotide reductase I define gemcitabine diphosphate binding and subunit assembly. Proc. Natl Acad. Sci. USA 103, 4028–4033 (2006).
CAS PubMed PubMed Central Article Google Scholar
Curran, M. P. & McKeage, K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs 69, 859–888 (2009).
CAS PubMed Article Google Scholar
Lynch, T. J., Okimoto, R. A., Supko, J. G. & Settleman, J. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
CAS PubMed Article Google Scholar
Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
CAS PubMed Article Google Scholar
Ou, S.-H. I. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit. Rev. Oncol. Hematol. 83, 407–421 (2012).
Yu, H. A. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR -mutant lung cancers. Clin. Cancer Res. 19, 2240–2247 (2013).
CAS PubMed PubMed Central Article Google Scholar
Recondo, G., Facchinetti, F., Olaussen, K. A., Besse, B. & Friboulet, L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat. Rev. Clin. Oncol. 15, 694–708 (2018).
CAS PubMed Article Google Scholar
Yun, C.-H. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105, 2070–2075 (2008).
CAS PubMed PubMed Central Article Google Scholar
Soria, J.-C. et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 16, 897–907 (2015).
CAS PubMed Article Google Scholar
Yu, H. A. & Pao, W. Afatinib — new therapy option for EGFR-mutant lung cancer. Nat. Rev. Clin. Oncol. 10, 551–552 (2013).
CAS PubMed PubMed Central Article Google Scholar
Harvey, R. D., Adams, V. R., Beardslee, T. & Medina, P. Afatinib for the treatment of EGFR mutation-positive NSCLC: a review of clinical findings. J. Oncol. Pharm. Pract. 26, 1461–1474 (2020).
留言 (0)